Press Releases Events and Presentations Press Releases Events & Presentations Keyword Search Year None202120202019201820172016 Madrigal Pharmaceuticals Announces Support of Fatty Liver Foundation’s Screening Fund to Improve Diagnosis and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) October 4, 2021 Madrigal Pharmaceuticals Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 5, 2021 Robert Waltermire Joins Madrigal Pharmaceuticals as Chief Pharmaceutical Development Officer August 2, 2021 Madrigal Pharmaceuticals Offers Patients Resmetirom in a Planned Open Label Active Treatment Extension of the Phase 3 MAESTRO-NAFLD-1 Clinical Study July 13, 2021 Madrigal Pharmaceuticals Completes Enrollment of the 52 Week Liver Biopsy Patient Population in the Phase 3 MAESTRO-NASH Study of Resmetirom June 30, 2021 Madrigal Pharmaceuticals Announces Presentation of Positive Clinical Data of Resmetirom from Open-Label Portion of Ongoing Phase 3 Clinical Trial MAESTRO-NAFLD-1 at The International Liver Congress™ 2021 June 25, 2021 Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences June 8, 2021 Madrigal Pharmaceuticals to Participate in UBS Global Healthcare Virtual Conference May 21, 2021 Madrigal Pharmaceuticals to Present at RBC Capital Markets Virtual 2021 Global Healthcare Conference on Wednesday, May 19, 2021 at 8:00 a.m. ET May 18, 2021 Alex Howarth Joins Madrigal Pharmaceuticals as Chief Financial Officer May 18, 2021 Madrigal Pharmaceuticals Reports 2021 First Quarter Financial Results and Highlights May 6, 2021 Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights February 25, 2021
